Company intelligence / Profile preview
Hansoh Pharmaceutical Group
Lianyungang, Jiangsu, Chinahspharm.com ↗
- Ownership
- Public · 3692
- Employees
- ~9000
- Development stage
- Commercial
01
Overview
Hansoh has seven innovative drugs approved in China with nine indications included in the National Reimbursement Drug List. Over 60 clinical trials are ongoing across more than 40 innovative drug candidates. The company’s revenue from innovative drugs reached RMB9.477 billion in 2024 (~$1.3B USD). Notable marketed products include Ameile® (aumolertinib) for NSCLC and Xinyue® (inebilizumab) for NMOSD.
- Therapeutic areas
- OncologyMetabolic DisordersImmunologyNeurologyInfectious Diseases
- Modalities
- Small moleculesmonoclonal antibodies (mAbs)antibody-drug conjugates (ADCs)synthetic peptidessiRNAfusion proteins
- Industry
- Biotech
02
Drug pipeline
72 assets71 more assets in the full pipeline.
Request access →03
Partnerships
GSK – out-license collaborationMSD – out-license collaborationTerns Pharmaceuticals – license agreement for NASH/cancer asset TRN‑000632 in Greater ChinaMultiple global biopharma partnerships via BD/in‑licensing/out‑licensing deals
Beyond the preview
Go deeper on Hansoh Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hansoh Pharmaceutical Group.